Robert L. Hollis

1.5k total citations
32 papers, 695 citations indexed

About

Robert L. Hollis is a scholar working on Reproductive Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Robert L. Hollis has authored 32 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Reproductive Medicine, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Robert L. Hollis's work include Ovarian cancer diagnosis and treatment (26 papers), PARP inhibition in cancer therapy (10 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Robert L. Hollis is often cited by papers focused on Ovarian cancer diagnosis and treatment (26 papers), PARP inhibition in cancer therapy (10 papers) and Endometrial and Cervical Cancer Treatments (8 papers). Robert L. Hollis collaborates with scholars based in United Kingdom, Japan and Canada. Robert L. Hollis's co-authors include Charlie Gourley, C. Simon Herrington, Michael Churchman, Yasushi Iida, Aikou Okamoto, Tzyvia Rye, Fiona Nussey, Simon P. Langdon, Melanie Mackean and Clare Bartos and has published in prestigious journals such as Nature Communications, The EMBO Journal and Cancer.

In The Last Decade

Robert L. Hollis

31 papers receiving 684 citations

Peers

Countries citing papers authored by Robert L. Hollis

Since Specialization

Citations

This map shows the geographic impact of Robert L. Hollis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Hollis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Hollis more than expected).

Fields of papers citing papers by Robert L. Hollis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Hollis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Hollis. The network helps show where Robert L. Hollis may publish in the future.

Co-authorship network of co-authors of Robert L. Hollis

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Hollis. A scholar is included among the top collaborators of Robert L. Hollis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Hollis. Robert L. Hollis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer 2025 ·European Journal of Cancer ·(unknown), Cheng Jin, Michael Churchman, Ian Croy, (unknown), (unknown), Marianne C. Stewart, (unknown), (unknown), Peter Sanderson, (unknown), C. Simon Herrington, Charlie Gourley, Robert L. Hollis	2
2	Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma 2025 ·Gynecologic Oncology ·Yasushi Iida, Michael Churchman, Robert L. Hollis, Sarah E. Taylor, Clare Bartos, Ian Croy, (unknown), Tzyvia Rye, (unknown), C. Simon Herrington, Charlie Gourley, Aikou Okamoto, John P. Thomson	0
3	High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma 2024 ·Gynecologic Oncology ·Robert L. Hollis, Richard Elliott, John C. Dawson, (unknown), (unknown), (unknown), (unknown), (unknown), Marta Llauradó Fernández, Michael Churchman, (unknown), Patricia Roxburgh, Asier Unciti‐Broceta, David M. Gershenson, C. Simon Herrington, Mark Carey, Neil O. Carragher, Charlie Gourley	5
4	Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes 2024 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), C. Simon Herrington, Robert L. Hollis	1
5	RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer 2024 ·Frontiers in Oncology ·Sarah Taylor, Robert L. Hollis, Charlie Gourley, C. Simon Herrington, Simon P. Langdon, Mark J. Arends	2
6	FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds 2024 ·Experimental and Molecular Pathology ·Sarah Taylor, Robert L. Hollis, Charlie Gourley, C. Simon Herrington, Simon P. Langdon, Mark J. Arends	2
7	Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome 2023 ·Gynecologic Oncology ·John P. Thomson, Robert L. Hollis, (unknown), (unknown), Michael Churchman, Koen Van de Vijver, Frederike Dijk, Alison Meynert, Clare Bartos, Tzyvia Rye, Ian Croy, (unknown), (unknown), (unknown), (unknown), Fiona Nussey, Christianne Lok, C. Simon Herrington, Charlie Gourley	8
8	Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma 2023 ·British Journal of Cancer ·C. Simon Herrington, (unknown), (unknown), Ian Croy, Michael Churchman, Robert L. Hollis	4
9	Molecular characteristics and clinical behaviour of epithelial ovarian cancers 2023 ·Cancer Letters ·Robert L. Hollis	54
10	Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma 2022 ·British Journal of Cancer ·Robert L. Hollis, Ian Croy, Michael Churchman, Clare Bartos, Tzyvia Rye, Charlie Gourley, C. Simon Herrington	25
11	Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification 2021 ·npj Precision Oncology ·Robert L. Hollis, Bárbara Stanley, John P. Thomson, Michael Churchman, Ian Croy, Tzyvia Rye, Clare Bartos, Fiona Nussey, Melanie Mackean, Alison Meynert, Colin A. Semple, Charlie Gourley, C. Simon Herrington	16
12	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma 2021 ·Cancers ·Robert L. Hollis, (unknown), Samantha L. Hopkins, Clare Bartos, Michael Churchman, Tzyvia Rye, Fiona Nussey, (unknown), (unknown), Gareth J. Inman, C. Simon Herrington, Charlie Gourley	10
13	Clear cell carcinoma of the ovary: a clinical and molecular perspective 2020 ·International Journal of Gynecological Cancer ·Yasushi Iida, Aikou Okamoto, Robert L. Hollis, Charlie Gourley, C. Simon Herrington	93
14	Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome 2020 ·Nature Communications ·Robert L. Hollis, John P. Thomson, Bárbara Stanley, Michael Churchman, Alison Meynert, Tzyvia Rye, Clare Bartos, Yasushi Iida, Ian Croy, Melanie Mackean, Fiona Nussey, Aikou Okamoto, Colin A. Semple, Charlie Gourley, C. Simon Herrington	83
15	Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse 2019 ·American Journal of Obstetrics and Gynecology ·Robert L. Hollis, Juliet Carmichael, Alison Meynert, Michael Churchman, (unknown), Tzyvia Rye, Melanie Mackean, Fiona Nussey, Colin A. Semple, C. Simon Herrington, Charlie Gourley	20
16	Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma 2019 ·Gynecologic Oncology ·Robert L. Hollis, Bárbara Stanley, Yasushi Iida, John P. Thomson, Michael Churchman, Tzyvia Rye, Melanie Mackean, Fiona Nussey, Charlie Gourley, C. Simon Herrington	22
17	Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors 2018 ·Gynecologic Oncology ·Bárbara Stanley, Robert L. Hollis, (unknown), (unknown), (unknown), Tzyvia Rye, (unknown), Melanie Mackean, Fiona Nussey, Michael Churchman, C. Simon Herrington, Charlie Gourley	22
18	Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations 2018 ·BMC Cancer ·Robert L. Hollis, Alison Meynert, Michael Churchman, Tzyvia Rye, Melanie Mackean, Fiona Nussey, Mark J. Arends, Andrew H. Sims, Colin A. Semple, C. Simon Herrington, Charlie Gourley	16
19	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer 2017 ·OncoTargets and Therapy ·Robert L. Hollis, Michael Churchman, Charlie Gourley	42
20	Genetic and molecular changes in ovarian cancer 2016 ·Cancer Biology and Medicine ·Robert L. Hollis, Charlie Gourley	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact